Publications

Sacks NC. 2013. Avoidable costs in U.S. healthcare: The $200 billion opportunity from using medicines more responsibly. IMS Health, June.

Sacks NC, Burgess JF, Cabral HJ, Pizer SD, McDonnell, ME. 2013. Cost sharing and decreased branded oral anti-diabetic medication adherence among elderly Part D Medicare beneficiaries. J Gen Intern Med 28(7):876–885.

Proctor DM, Suh M, Thompson CM, Harris MA. Mode of action evaluation for hexavalent chromium-induced lung cancer. Presented at Society of Toxicology 52nd Annual Meeting, San Antonio, TX, March 2013.

Mitchell M, Lowe K, Fryzek J. 2012. A multisource approach to improving epidemiologic estimates: Application to global B-cell malignancies. ISRN Oncol 2012:129713; 10.5402/2012/129713.

Kanas GP, Taylor A, Primrose JN, Langeberg WJ, Kelsh MA, Mowat FS, et al. 2012. Survival after liver resection in metastatic colorectal cancer: Review and meta-analysis of prognostic factors. Clin Epidemiol 4:283–301.

O’Brien TJ, Hao D, Suh M, Proctor D, Thompson CM, Harris MA, Parsons BL, Meyers MB. K-ras codon 12 GGT to GAT mutation is not elevated in the duodenum of mice subchronically exposed to hexavalent chromium in drinking water. Presented at Society of Toxicology 51st Annual Meeting, San Francisco, CA, March 2012.

Lau EC, Mowat FS, Kelsh MA, Legg JC, Engel-Nitz NM, Watson HN, et al. 2011. Use of electronic medical records (EMR) for oncology outcomes research: Assessing the comparability of EMR information to patient registry and health claims data. Clin Epidemiol 3:259–272.

Cyr PL, Slawsky KL, Olchanski N, Krasa HB, Goss TF, Zimmer C, Hauptman PJ. 2011. Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure. Am J Health Syst Pharm 68(4):328-333; doi: 10.2146/ajhp100217.

Gatto NM, Kelsh MA, Mai DH, Suh M, Proctor DM. 2010. Occupational exposure to hexavalent chromium and cancers of the gastrointestinal tract: A meta-analysis. Cancer Epidemiol 34(4):388-399.

Olchanski N, Slawsky KA, Plent S, Kado C, Cyr PL. 2010. Economic impact of switching to bivalirudin for a primary percutaneous coronary intervention in a U.S. hospital. Hosp Prac 38(4):138-146; doi: 10.3810/hp.2010.11.351.